Kybernin P (Antithrombin Iii)

Antithrombin III binds to and inactivates thrombin and several other serine proteases in the clotting cascade. By accelerating the natural inhibition of these enzymes, it reduces clot formation and enhances the anticoagulant effect of heparin, helping to maintain normal blood fluidity.

The dosage of Kybernin P is individualized. A qualified prescriber determines the amount and frequency based on the patient’s antithrombin activity, clinical condition, and response to therapy. Dosing is adjusted according to laboratory monitoring and therapeutic goals.

Data on the use of antithrombin III concentrates during pregnancy and lactation are limited. The potential benefits must be weighed against possible risks, and treatment decisions should be made by a specialist in consultation with the patient’s obstetric care team.

To order Kybernin P, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and import documentation.

Unlike direct oral anticoagulants, Kybernin P supplies the natural protein antithrombin III, which specifically enhances heparin activity. It is particularly useful in patients with antithrombin deficiency or heparin resistance, whereas other anticoagulants act through different mechanisms and may not correct the underlying protein deficiency.

Kybernin P must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Before administration, inspect the solution for any particles or discoloration and use aseptic technique.

Kybernin P is given as an intravenous injection. The product is reconstituted according to the manufacturer’s instructions and infused slowly under medical supervision. Infusion rates and total volume are adjusted based on the patient’s weight, antithrombin levels, and clinical response.

Serious risks include severe allergic reactions such as anaphylaxis, unexpected bleeding or hemorrhage, and paradoxical thrombotic events despite therapy. Prompt recognition of these events and immediate medical intervention are essential to mitigate complications.

Kybernin P is contraindicated in patients with known hypersensitivity to antithrombin III or any excipients in the formulation, and in individuals with active, uncontrolled bleeding. Caution is also advised for patients with severe renal impairment or those receiving multiple anticoagulants without close monitoring.